These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 14039067)

  • 21. The influence of enzyme induction on polymorphic sparteine oxidation.
    Eichelbaum M; Mineshita S; Ohnhaus EE; Zekorn C
    Br J Clin Pharmacol; 1986 Jul; 22(1):49-53. PubMed ID: 3741726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Substantial rise in sparteine metabolic ratio during haloperidol treatment.
    Gram LF; Debruyne D; Caillard V; Boulenger JP; Lacotte J; Moulin M; Zarifian E
    Br J Clin Pharmacol; 1989 Feb; 27(2):272-5. PubMed ID: 2713222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sparteine oxidation polymorphism in Denmark.
    Brøsen K; Otton SV; Gram LF
    Acta Pharmacol Toxicol (Copenh); 1985 Nov; 57(5):357-60. PubMed ID: 4090995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A nuclear magnetic resonance study of sparteine delta metabolite structure.
    Ebner T; Meese CO; Fischer P; Eichelbaum M
    Drug Metab Dispos; 1991; 19(5):955-9. PubMed ID: 1686242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sparteine oxidation polymorphism in Greenlanders living in Denmark.
    Brøsen K
    Br J Clin Pharmacol; 1986 Oct; 22(4):415-9. PubMed ID: 3768256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of cytochrome P450 2D6-catalyzed sparteine metabolism in humans.
    Ebner T; Meese CO; Eichelbaum M
    Mol Pharmacol; 1995 Dec; 48(6):1078-86. PubMed ID: 8848008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benzo(a)pyrene metabolism in hepatic microsomes from female DA rats with a genetic sparteine oxidation deficiency.
    Schlede E; Roots I
    Toxicol Lett; 1985 Dec; 29(1):5-10. PubMed ID: 4082205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs.
    Otton SV; Inaba T; Kalow W
    Life Sci; 1984 Jan; 34(1):73-80. PubMed ID: 6141510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
    Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
    Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between the acetylator and the sparteine hydroxylation polymorphisms.
    Harmer D; Evans DA; Eze LC; Jolly M; Whibley EJ
    J Med Genet; 1986 Apr; 23(2):155-6. PubMed ID: 3712391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sparteine oxidation polymorphism: a family study.
    Brøsen K; Otton SV; Gram LF
    Br J Clin Pharmacol; 1986 Jun; 21(6):661-7. PubMed ID: 3741716
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apparent mendelian recessive inheritance of sparteine metabolism in an extended Japanese family.
    Chiba K; Kato J; Hashimoto K; Ishizaki T
    Eur J Clin Pharmacol; 1988; 34(6):661-2. PubMed ID: 3169120
    [No Abstract]   [Full Text] [Related]  

  • 33. Regioselectivity and stereoselectivity of the metabolism of the chiral quinolizidine alkaloids sparteine and pachycarpine in the rat.
    Ebner T; Meese CO; Eichelbaum M
    Xenobiotica; 1991 Jul; 21(7):847-57. PubMed ID: 1776260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.
    Herchuelz A; Gangji D; Derenne F; Jeanniot JP; Douchamps J
    Br J Clin Pharmacol; 1991 Jan; 31(1):73-6. PubMed ID: 2015173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.
    Eichelbaum M; Bertilsson L; Säwe J
    Br J Clin Pharmacol; 1983 Mar; 15(3):317-21. PubMed ID: 6849767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin.
    Brøsen K; Gram LF; Kragh-Sørensen P
    Ther Drug Monit; 1991 Mar; 13(2):177-82. PubMed ID: 2053127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2-Hydroxylation of ethinyloestradiol in relation to the oxidation of sparteine and antipyrine.
    Back DJ; Maggs JL; Purba HS; Newby S; Park BK
    Br J Clin Pharmacol; 1984 Oct; 18(4):603-7. PubMed ID: 6487500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Debrisoquine/sparteine-type polymorphic drug metabolism in wild Clethrionomys rufocanus.
    Hoshi H; Masuda M; Yamamoto Y; Suimamoto Y; Kazusaka A; Fujita S
    Drug Metab Dispos; 1995 Nov; 23(11):1301-3. PubMed ID: 8591735
    [No Abstract]   [Full Text] [Related]  

  • 39. Interactions of bupranolol with the polymorphic debrisoquine/sparteine monooxygenase (CYP2D6).
    Pressacco J; Muller R; Kalow W
    Eur J Clin Pharmacol; 1993; 45(3):261-4. PubMed ID: 8276051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.
    Nielsen MD; Brøsen K; Gram LF
    Br J Clin Pharmacol; 1990 Mar; 29(3):299-304. PubMed ID: 2310654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.